Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

APD125

Broader (2)

Phenylurea CompoundsPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [35S]GTPγS Binding Assays.
G protein-coupled receptors (GPCRs), also known as 7-transmembrane receptors, are the single largest class of drug targets… Expand
Is this relevant?
2018
2018
Drug Repurposing Patent Applications October-December 2017.
 
Is this relevant?
2018
2018
The Involvement of 5-HT 2A Receptor in the Regulation of Sleep and Wakefulness, and the Potential Therapeutic Use of Selective 5-HT 2A Receptor Antagonists and Inverse Agonists for the Treatment of…
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These… Expand
Is this relevant?
Review
2017
Review
2017
A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations (P6.088)
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations… Expand
Is this relevant?
Review
2017
Review
2017
Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists Specifically Promote Slow Wave Sleep (Stage N3) in Man
Several drug classes are widely prescribed when difficulties with sleep induction or sleep maintenance occur, as is the case in… Expand
Is this relevant?
Review
2017
Review
2017
New Therapeutic Strategies for Lewy Body Dementias
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
2016
2016
The Effects of Benzodiazepine and Nonbenzodiazepine Agents, Ramelteon, Low-dose Doxepin, Suvorexant, and Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists on Sleep and Wakefulness
Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the… Expand
  • table 1
  • table 2
  • table 4
  • table 3
  • table 5
Is this relevant?
Review
2011
Review
2011
Serotonin control of sleep-wake behavior.
Based on electrophysiological, neurochemical, genetic and neuropharmacological approaches, it is currently accepted that… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.
5-Hydroxytryptamine (5-HT)(2A) receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2010
2010
Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE